Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"I am delighted to join Amarantus at a time when the Company is preparing for the introduction of this highly specific and sensitive diagnostic assay for Alzheimer's disease into the marketplace. Market launch of diagnostic products requires significant strategy in regards to initial commercial sales, regulatory matters, reimbursement and other important considerations. I am looking forward to helping the team at Amarantus make value-building decisions for both the short-term and long-term success of LymPro commercial launch and ultimate regulatory approval for widespread use."
http://globenewswire.com/news-release/2013/09/03/571030/10047081/en/Amarantus-Appoints-Dr-Colin-Bier-to-Advisory-Board-for-LymPro-Commercialization.html
Dr. Rubinfield, cofounder of AMGEN added to corporate advisory board.
“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson’s, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company’s new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.”
AMBS “The data on MANF continues to return more favorable results than other molecules currently in clinical development as disease-modifying treatments for Parkinson’s disease,” said Dr. Joseph Rubinfeld, Amgen co-founder and current member of the Company’s Board of Advisors. “We intend to conduct select additional experiments to understand why this appears to be the case while we continue the IND-enabling studies that have already been initiated. We believe these additional data points will further distinguish MANF from competitors in the field, and will deliver significant value in the near-term.”
AMBS BOD's resume's rival any other Pharma :
Dr. Joseph Rubinfeld
* Amarantus BioSci., BOD
* Amgen, Co-founder
* Bristol Myers Squibb, SSOP
* Cetus Corp., Sr. Dir.
* SuperGen, Co-founder, Pres. & CEO
* Inventor - Amoxicillin
* Inventor - Biodegradable Detergent
* Inventor - Polaroid Instimatic Film
* Columbia Univ., PhD Chemistry
Owen Garrick, MD MBA
* Amarantus BioSci., BOD
* Bridge Clinical Research, Pres. & COO
* AMA Foundation, Pres.
* McKesson Corp., Dir. Corp. Strategy & Business Devl.
* Novartis, Co-Head M&A's
* Goldman Sachs, Associate
* Yale School of Medicine, MD
* Wharton School of Business, MBA
* Princeton Univ., AB
* Princeton Univ., BOD - Natl. Fund Raising Bd.
Mark Benedyk, PhD
* Amarantus BioSci., BOD
* Rila Partners LLC, Managing Partner
* Center for Drug R&D Ventures Inc., Dir.
* CNS Regenerative Medicine Found., BOD Trans. Medicine Advisory
* The Pfizer Incubator (TPI), Dir.
* The Pfizer Incubator (TPI), Portfolio Seat - Investments
* Ascenta Therapeutics, Business Devl.
* Optimer Biotech., Business Devl.
* Aurora BioSci., aka Vertex Pharma., Business Devl.
* Elan Pharma., Business Devl.
* The Rockefeller Univ., PhD, Developmental Genetics
* Stanford Univ., MBA
* Univ. of Virginia Darden School of Business, Grad. Cert.
* Univ. of Michigan, BS, Microbiology & BS, Botany
Clinton Allen, MSc
* Amarantus BioSci., BOD
* Bristol Myers Squibb, Dir. Corp. Compliance Audit
* Bristol Myers Squibb, Sr. Dir. Risk Management
* Bristol Myers Squibb, Dir. Prod. Devel. & Commercialization
* Bristol Myers Squibb, Dir. In-licensing & Business Devel.
* Tufts Univ., MSc. Environmental Mngt. & Sciences
* Capitan, US Army
Continued AMBS's MANF development for the treatment of PD is warranted based on the results of this present study, the known mechanism of action and published literature.
My Speculation is Validation was requested by JV Partner / Or Buyout Candidate... We shall soon find out..
http://ir.stockpr.com/amarantus/all-sec-filings#document-7384-0001144204-13-020765
GL2ALL
Amarantus Seeks Candidate For PD-LID:
On May 22, 2013, Amarantus entered into a letter of intent to in-
license a Phase II drug candidate in L-Dopa-Induced Dyskinesia (LID) in patients with Parkinson's Disease from an undisclosed third party. Once the license is complete, Amarantus plans to initiate a Phase IIb trial within 12 months.
AMBS Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson’s Disease
http://www.onemedplace.com/blog/archives/12410
going back to his original comment.... yes.. the Medgenesis trials for GDNF being positive will be a huge boost for MANF since it was shown to be superior..
MJFF Grants were not as important now as AMBS is changing its Focus to LymPro and Orphan IND's ....
But I will not be surprised if they do get another grant for PD now that they have someone to focus on this type of funding..
$AMBS $800 Million PLUS Revenue Generating Potential coming into the picture fast and furiously ..
Dr. Simon is a world-renowned expert in working with Alzheimer's disease biomarkers, and also has significant expertise in the development of in-vitro diagnostics;
http://seekingalpha.com/instablog/200555-qualitystocks/1713571-dr-adam-j-simon-joins-amarantus-bioscience-inc-ambs-board-of-advisors
AMBS / Nascent AD Biomarker Market- Provides Opportunities for Companies with Innovative Products to Establish their Presence
There are also several companies actively developing fluid-based biomarker panel assays for AD, including Innogenetics, which has produced assay kits for amyloid and tau proteins that are widely used in academic research and in clinical drug development. Some of these Innogenetics AD biomarker kits have received CE (Conformité Européenne) marking in the EU, but to date, none are FDA approved for clinical diagnostic use in the US.
Blood-based assays for AD biomarkers hold great promise as screening tests that can be widely applied in a cost-effective manner and are a major unmet need for AD. Several companies, such as Exonhit, Ctyox, Proteome Biosciences, DiaGenic, and Amarantus, have products in development that, if validated, may satisfy this need.
http://pipelinereview.com/index.php/2013080151685/More-News/Nascent-AD-Biomarker-Market-Provides-Opportunities-for-Companies-with-Innovative-Products-to-Establish-their-Presence.html
AMBS - Perhaps most interesting from a time-to-market standpoint, is the emerging evidence that MANF has activity in certain rare and ultra-rare orphan diseases. The orphan drug strategy that management is pursuing will seek a path to commercialize MANF as expeditiously and cost-effectively as possible, and potentially faster than Parkinson's, Traumatic Brain Injury or Myocardial Infarction. We are evaluating the possibilities of the MANF program in various orphan disease areas through our recent grant from the Center of Excellence for Apoptosis Research and collaborations with academic labs. We expect this process to be completed within a calendar year, and we will be updating shareholders on an on-going basis regarding results of experiments as data becomes available. The key advantage to this strategy is that the Investigational New Drug (IND) protocols required for our Parkinson's program will overlap with our orphan drug program; therefore, an additional IND should be attainable in the same timeframe.
http://ir.stockpr.com/amarantus/company-news/detail/353/amarantus-biosciences-issues-ceo-letter-to-shareholders
ZACKS Small Cap Research: AMBS PUSHING FORWARD WITH LYMPRO
http://scr.zacks.com/files/June%2019%202013_AMBS_Napodano_v001_n50g1c.pdf
AMBS Orphan Disease Targets increasing for MANF :
Fairbanks disease (MED)MULTIPLE EPIPHYSEAL DYSPLASIA is listed as a "rare disease" by the Office of Rare Diseases (ORD) of the National Institutes of Health (NIH). This means that Fairbank disease, or a subtype of Fairbank disease, affects less than 200,000 people in the US population.
and Prion Disease us Ultra Rare only 300 people per year affected in the US.
Seems as if Dr. Rubinfeld & AMBS are on the ball with this Orphan IND strategy.
AMBS's MANF Diabetes Research Program
http://www.evaluategroup.com/Universal/View.aspx?type=Search&query=MANF
AMBS has all the patents to MANF
market intel ....i wonder who is logging into this site?
From AMBS Twitter feed dated Sept 23rd 2013:
Quote:
The assay is currently performing very well, and BD expects to deliver the final report on this phase of the project in the next 2 weeks.
BD's analytical performance report for the assay is awaiting final approval prior to distribution to Amarantus
Also on 8k that same day.
major research institute in California can't speak who they are because we're under NDA.
Quote:As I said before we are undergoing a strategic review and what's really driving is the first data set that we've received now from two independent groups one in Miami and another at the major research institute in California can't speak who they are because we're under NDA. -
http://www.earningsimpact.com/Transcript/83747/AMBS/Amarantus-BioSciences%2c-Inc---15th-Annual-Rodman-and-Renshaw-Global-Investment-Conference#sthash.JyvbDd96.dpbs
Genomics Institute of the Novartis Research Foundation
California
http://www.gnf.org/contact/
MANF’s Orphan Strategy Coming into Focus in Retinitis Pigmentosa
Ophthalmology has taken on significantly greater interest as of late from major players in the biopharmaceutical industry for this $10 billion market.
We believe RP is just the beginning of the MANF story in ophthalmology. Other neurotrophic factors have begun to show promise in many diseases in the area and the data announced earlier this week scientifically supports development in many therapeutic indications beyond RP in ophthalmology, including Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD affects approximately 15 million people in the United States. 14%-24% of the U.S. population age 65-74 years and 35% of people aged 75 years or older have the disease[1]. Currently, there are no available disease-modifying treatments for Dry AMD, making the opportunity for MANF so attractive. MANF’s development in RP may accelerate the pathway for it to reach the significantly larger Dry AMD patient population by proving cone and rod protection in humans in the smaller RP population first.
http://www.thechairmansblog.com/gerald-commissiong/2013-08/ophthalmology-manfs-orphan-strategy-coming-into-focus-in-retinitis-pigmentosa.html
AMBS Laying the Groundwork for an Up-Listing
we are focused on taking key fundamental value-building steps to advance LymPro towards commercialization, projected for the second half of 2014. We are also reprioritizing our pipeline for MANF as new data is gathered in various orphan indications and planning the critical path to first-in-man studies. As we move these programs forward, the funds raised gives the Company the necessary resources to attract the key management talent necessary to actualize these plans and further lend credibility to our programs by having proven teams executing them. As data continues to flow in, we believe we will be in a position to fundamentally improve shareholder value in the coming months and ultimately put the Company in a position to up-list to a national exchange.
http://www.thechairmansblog.com/gerald-commissiong/2013-09/financial-stability-heading-into-2014-laying-the-groundwork-for-an-up-listing.html
And also add to it, the financing raises were mentioned in Jason Napodano's AMBS / LymPro - Gamechanger articles and Valuations reports... that many here quoted regularly.
I know why some are complaining.. others are just playing dumb..
GL2ALL
LYMPRO TEST(R)
AMBS will focus on entering into agreements w/ top tier clinical sites to support LymPro clinical studies for AD & other indications
http://ir.stockpr.com/amarantus/all-sec-filings#document-10684-0001144204-13-052051
AD plus OTHER INDICATIONS = $500 Million Dollar Revenue PLUS $Revenue for other Indication(s) ??? How many more How much more revenue potential....
means nothing to me... trust me, i mean that from the bottom of my heart
from August 21 to September 3rd AMBS had almost a 300% gain from .034 to .089 ...If you are not sure when to Buy, you should follow people who have profited big here.
Answer to your AMBS S-1 investors question is: NO
I am having trouble finding where AMBS said they would release results in 3rd quarter, I see where the said the Validation studies would take place in the 3rd quarter and they delivered.. can you point it out?
they said they would pick the CED partner in the 3rd quarter and they delivered..
they said they would announce orphan IND's for MANF they have pointed out 1 and the other is under a non disclosure agreement... they delivered
When did BD turn over their report? we do not know, and no I would not hope it is something simple they can just post on the internet with a link after all the Validation study is something that cost AMBS probably around $1 Million (guesstimate)
its a delay in your eyes you have your point of view, i think they are just following their plan and delivering on their milestones..
GL2ALL
again its a Delay in your mind only because you assumed the Company AMBS would just flip you a copy of the BD report without looking it over.. be realistic here and stop asssuming..
This helps Lympro. Don't be frustrated . Thanks for the post
Wrong info once again. Lympro is a licensing deal.
Nuropro came with the other ip they bought for $40k
Get your false statements in order.
Thanks.
You realize thats when LymPro Revenue starts being generated right?
Yeah better go for AMBS 2015. Cause 2014 is covered.
You both need to relax. Quarter just ended , BD is turning in their report , AMBS has to review it to make sure its right. BD could be making a bid, or someone else. In regards to The orphan data he said they were under an NDA ,the agreement for the Use of the discovered IND for MANF is probably not finalized. The institute will surely want their cut if it gets to commercialization.
Gerald just registered Lymprotest.com
Chill
Check who the Domain is registered to now..
lymprotest.com
AMBS
Yes they should be back on track in around 120 days if all goes well. Lets keep in mind The test works and that was never in question.
Great $ATOS buying opportunity.
not really, in this case they cannot sit on it for more than 3 days after the 2 weeks have past unless they indicate that BD has not given them the report when it was promised, thats my Opinion.. someone correct me if i'm wrong.
From AMBS Twitter feed dated Sept 23rd 2013:
Quote:
The assay is currently performing very well, and BD expects to deliver the final report on this phase of the project in the next 2 weeks.
BD's analytical performance report for the assay is awaiting final approval prior to distribution to Amarantus
Also on 8k that same day.
No , thats not right.
You got that right..
MANF will bring AMBS to billion dollar status.
Also lets not forget , AMBS was looking into LymPro possibly for other IND's as well
Amarantus to Evaluate LymPro Test as a Diagnostic and Prognostic for Chronic Traumatic Encephalopathy
http://ir.stockpr.com/amarantus/company-news/detail/784/amarantus-to-evaluate-lympro-test-as-a-diagnostic-and-prognostic-for-chronic-traumatic-encephalopathy
From AMBS Twitter feed dated Sept 23rd 2013:
The assay is currently performing very well, and BD expects to deliver the final report on this phase of the project in the next 2 weeks.
BD's analytical performance report for the assay is awaiting final approval prior to distribution to Amarantus
Can you start here and then check back, as Jason Napodono is working on an updated Valuation of AMBS based on new developments..
http://www.zacks.com/stock/news/100015/Initiating-Coverage-Of-Amarantus-Credibility-vs-Perception
But this is a conservative .25
AMBS Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson’s Disease
http://www.onemedplace.com/blog/archives/12410
going back to his original comment.... yes.. the Medgenesis trials for GDNF being positive will be a huge boost for MANF since it was shown to be superior..
MJFF Grants were not as important now as AMBS is changing its Focus to LymPro and Orphan IND's ....
But I will not be surprised if they do get another grant for PD now that they have someone to focus on this type of funding..
The partnership between JDRF and GNF aims to develop a series of clinical candidates. Initial efforts are focused on developing therapies that promote pancreatic beta cell regeneration and survival. GNF and JDRF have seeded the pipeline with several existing programs at GNF. GNF and JDRF seek to build upon this pipeline through collaborations with leading diabetes investigators. For questions about the GNF-JDRF partnership, please contact diabetes@gnf.org
Cell regeneration and survival = AMBS's MANF has shown these atributes..
http://www.gnf.org/collaborations/jdrf/